NO20054778L - Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer - Google Patents

Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer

Info

Publication number: NO20054778L
Authority: NO; Norway
Prior art keywords: rapamycin; inflammatory; treatment; combination; pharmaceutical compositions
Prior art date: 2003-03-17

Application number

NO20054778A

Other languages

English (en)

Norwegian (no)

Other versions

NO20054778D0 (no

Inventor

Henrietta Moore

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-17

Filing date

2005-10-17

Publication date

2005-12-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33032928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20054778(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-03-17 Priority claimed from GB0306070A external-priority patent/GB0306070D0/en

2003-03-25 Priority claimed from GB0306868A external-priority patent/GB0306868D0/en

2003-08-15 Priority claimed from GB0319226A external-priority patent/GB0319226D0/en

2005-10-17 Application filed by Novartis Ag filed Critical Novartis Ag

2005-10-17 Publication of NO20054778D0 publication Critical patent/NO20054778D0/no

2005-12-19 Publication of NO20054778L publication Critical patent/NO20054778L/no

Links

QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 3
201000010099 disease Diseases 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
230000002757 inflammatory effect Effects 0.000 title abstract 2
230000001404 mediated effect Effects 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 2
229960002930 sirolimus Drugs 0.000 title abstract 2
KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 title 1
229960005330 pimecrolimus Drugs 0.000 title 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
206010061598 Immunodeficiency Diseases 0.000 abstract 1
208000029462 Immunodeficiency disease Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000007813 immunodeficiency Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Immunology (AREA)
Hematology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Obesity (AREA)
Biochemistry (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicinal Preparation (AREA)

NO20054778A 2003-03-17 2005-10-17 Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer NO20054778L (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0306070A GB0306070D0 (en)	2003-03-17	2003-03-17	Organic compounds
GB0306868A GB0306868D0 (en)	2003-03-25	2003-03-25	Organic compounds
GB0319226A GB0319226D0 (en)	2003-08-15	2003-08-15	Organic compounds
PCT/EP2004/002714 WO2004082681A1 (en)	2003-03-17	2004-03-16	Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation- and ummunologically-mediated diseases

Publications (2)

Publication Number	Publication Date
NO20054778D0 NO20054778D0 (no)	2005-10-17
NO20054778L true NO20054778L (no)	2005-12-19

Family

ID=33032928

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20054778A NO20054778L (no)	2003-03-17	2005-10-17	Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer

Country Status (25)

Country	Link
US (1)	US20060154952A1 (is)
EP (1)	EP1608368B8 (is)
JP (1)	JP2006515017A (is)
KR (1)	KR100855140B1 (is)
AR (1)	AR043504A1 (is)
AT (1)	ATE409479T1 (is)
AU (1)	AU2004222563B2 (is)
BR (1)	BRPI0408423A (is)
CA (2)	CA2633287A1 (is)
CL (1)	CL2004000535A1 (is)
DE (1)	DE602004016830D1 (is)
EC (1)	ECSP056006A (is)
ES (1)	ES2315648T3 (is)
HR (1)	HRP20050800A2 (is)
IS (1)	IS8028A (is)
MA (1)	MA27671A1 (is)
MX (1)	MXPA05009934A (is)
MY (1)	MY137868A (is)
NO (1)	NO20054778L (is)
PE (1)	PE20050313A1 (is)
PL (1)	PL1608368T3 (is)
PT (1)	PT1608368E (is)
TN (1)	TNSN05197A1 (is)
TW (2)	TW200503703A (is)
WO (1)	WO2004082681A1 (is)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20070070184A (ko) *	2004-10-28	2007-07-03	와이어쓰	자궁근종의 치료에 있어서 ｍＴＯＲ 억제제의 용도
EP2278966B1 (en) *	2008-03-21	2019-10-09	The University of Chicago	Treatment with opioid antagonists and mtor inhibitors
AU2013205002B2 (en) *	2008-03-21	2016-09-15	The University Of Chicago	Treatment with opioid antagonists and mTOR inhibitors
MX2011007647A (es)	2009-01-21	2011-09-01	Amgen Inc	Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
RU2449806C1 (ru) *	2010-11-30	2012-05-10	Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию"	Способ лечения красного плоского лишая слизистой оболочки полости рта
WO2014117035A1 (en)	2013-01-24	2014-07-31	Transderm, Inc.	COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
US10307370B2 (en)	2013-10-08	2019-06-04	AI Therapeutics, Inc.	Rapamycin for the treatment of lymphangioleiomyomatosis
DK3125875T3 (da) *	2014-04-04	2023-07-24	Ai Therapeutics Inc	Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
KR20170095807A (ko)	2014-10-07	2017-08-23	램 테라퓨틱스, 인코포레이티드	폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제
MY188430A (en)	2015-04-10	2021-12-08	Amgen Inc	Interleukin-2 muteins for the expansion of t-regulatory cells
JP7108631B2 (ja)	2017-01-06	2022-07-28	パルヴェラセラピューティクス、インク．	ｍＴＯＲ阻害剤の無水組成物およびその使用方法
US11000513B2 (en)	2018-07-02	2021-05-11	Palvella Therapeutics, Inc.	Anhydrous compositions of mTOR inhibitors and methods of use
AU2020328038B2 (en)	2019-08-13	2025-10-09	Amgen Inc.	Interleukin-2 muteins for the expansion of T-regulatory cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0427680T3 (da) *	1989-11-09	1995-12-18	Sandoz Ltd	Heteroatom-holdige cykliske forbindelser
GB9221220D0 (en) *	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
BE1009856A5 (fr) *	1995-07-14	1997-10-07	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
EP1208847B8 (en) *	1996-07-30	2007-02-14	Novartis AG	Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions
GB9723669D0 (en) *	1997-11-07	1998-01-07	Univ Aberdeen	Skin penetration enhancing components
JP2005512946A (ja) *	2001-05-09	2005-05-12	ノバルティスアクチエンゲゼルシャフト	選択的免疫調節法
TW200306826A (en) *	2002-01-10	2003-12-01	Novartis Ag	Drug delivery systems for the prevention and treatment of vascular diseases
DE10393059D2 (de) *	2002-05-09	2005-05-04	Hemoteq Gmbh	Verbindungen und Verfahren zur hemokompatiblen Beschichtung von Oberflächen

2004
- 2004-03-08 AR ARP040100730A patent/AR043504A1/es not_active Application Discontinuation
- 2004-03-15 TW TW093106848A patent/TW200503703A/zh unknown
- 2004-03-15 PE PE2004000273A patent/PE20050313A1/es not_active Application Discontinuation
- 2004-03-15 TW TW097116133A patent/TW200835484A/zh unknown
- 2004-03-16 CL CL200400535A patent/CL2004000535A1/es unknown
- 2004-03-16 MX MXPA05009934A patent/MXPA05009934A/es not_active Application Discontinuation
- 2004-03-16 BR BRPI0408423-3A patent/BRPI0408423A/pt not_active IP Right Cessation
- 2004-03-16 PT PT04720871T patent/PT1608368E/pt unknown
- 2004-03-16 PL PL04720871T patent/PL1608368T3/pl unknown
- 2004-03-16 ES ES04720871T patent/ES2315648T3/es not_active Expired - Lifetime
- 2004-03-16 EP EP04720871A patent/EP1608368B8/en not_active Expired - Lifetime
- 2004-03-16 CA CA002633287A patent/CA2633287A1/en not_active Abandoned
- 2004-03-16 DE DE602004016830T patent/DE602004016830D1/de not_active Expired - Fee Related
- 2004-03-16 KR KR1020057017469A patent/KR100855140B1/ko not_active Expired - Fee Related
- 2004-03-16 CA CA002517671A patent/CA2517671A1/en not_active Abandoned
- 2004-03-16 AT AT04720871T patent/ATE409479T1/de not_active IP Right Cessation
- 2004-03-16 JP JP2005518678A patent/JP2006515017A/ja active Pending
- 2004-03-16 WO PCT/EP2004/002714 patent/WO2004082681A1/en not_active Ceased
- 2004-03-16 HR HR20050800A patent/HRP20050800A2/xx not_active Application Discontinuation
- 2004-03-16 US US10/547,185 patent/US20060154952A1/en not_active Abandoned
- 2004-03-16 AU AU2004222563A patent/AU2004222563B2/en not_active Ceased
- 2004-03-16 MY MYPI20040914A patent/MY137868A/en unknown
2005
- 2005-08-17 TN TNP2005000197A patent/TNSN05197A1/en unknown
- 2005-09-08 EC EC2005006006A patent/ECSP056006A/es unknown
- 2005-09-15 IS IS8028A patent/IS8028A/is unknown
- 2005-09-30 MA MA28526A patent/MA27671A1/fr unknown
- 2005-10-17 NO NO20054778A patent/NO20054778L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1608368A1 (en)	2005-12-28
CA2517671A1 (en)	2004-09-30
ES2315648T3 (es)	2009-04-01
JP2006515017A (ja)	2006-05-18
MY137868A (en)	2009-03-31
AR043504A1 (es)	2005-08-03
HK1086743A1 (en)	2006-09-29
MXPA05009934A (es)	2006-03-21
EP1608368B8 (en)	2009-06-10
PT1608368E (pt)	2009-01-27
DE602004016830D1 (de)	2008-11-13
TNSN05197A1 (en)	2007-06-11
NO20054778D0 (no)	2005-10-17
WO2004082681B1 (en)	2004-11-25
KR20050110023A (ko)	2005-11-22
WO2004082681A1 (en)	2004-09-30
PL1608368T3 (pl)	2009-03-31
BRPI0408423A (pt)	2006-03-21
AU2004222563A1 (en)	2004-09-30
TW200503703A (en)	2005-02-01
HRP20050800A2 (en)	2006-11-30
ATE409479T1 (de)	2008-10-15
ECSP056006A (es)	2006-01-27
EP1608368B1 (en)	2008-10-01
IS8028A (is)	2005-09-15
KR100855140B1 (ko)	2008-08-28
CL2004000535A1 (es)	2005-01-14
AU2004222563B2 (en)	2006-11-02
CA2633287A1 (en)	2004-09-30
TW200835484A (en)	2008-09-01
MA27671A1 (fr)	2005-12-01
PE20050313A1 (es)	2005-06-14
US20060154952A1 (en)	2006-07-13

Legal Events

Date	Code	Title	Description
2009-10-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20076059L (no)	2008-01-30	2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
NO20056192L (no)	2005-12-27	Kapaseinhibitorer og anvendelse derav
NO20054778L (no)	2005-12-19	Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer
NO20063761L (no)	2006-10-23	Sulfonamidderivater for behandling av sykdommer
NO20051100L (no)	2005-05-02	Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
AP2008A (en)	2009-06-29	Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders; process for their preparation and pharmaceutical compositions containing them
ATE382353T1 (de)	2008-01-15	Substiuierte piperidine als melanocortinrezeptor- modulatoren
NO20070489L (no)	2007-03-07	3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20072371L (no)	2007-07-12	Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
NO20062561L (no)	2006-09-08	Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
EA200802058A1 (ru)	2009-06-30	Производные циклоалкиламинокислот и их фармацевтические композиции
NO20084005L (no)	2008-09-19	Aminderivater
ATE361288T1 (de)	2007-05-15	N-(3,-dimethylindolin-6-yl)ä2-ä(4-
NO20063928L (no)	2006-10-31	Substituerte kinolinforbindelser
DE602004024900D1 (de)	2010-02-11	Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
NO20054905L (no)	2006-01-25	2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
CY1109055T1 (el)	2014-07-02	11-((4r,6r)-4,5,6-τριϋδροξυ-3-(r)-υδροξυ-εξυλοκαρβαμοϋλο)-ενδεκαϊνικο οξυ
NO20076195L (no)	2008-02-27	Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
NO20074258L (no)	2007-11-27	Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20062983L (no)	2006-07-24	Sulfonamid-derivater for behandling av sykdommer
NO20061363L (no)	2006-04-24	Pyrazolo- og imidazo- pyrimidinderivater
DE602004012418D1 (de)	2008-04-24	Piperazinderivate und anwendungsverfahren
NO20073170L (no)	2007-06-22	Kaspaseinhibitorer og anvendelse derav
ATE406353T1 (de)	2008-09-15	Piperidin-derivaten und deren verwendung bei der behandlung von durch chemokinen oder h1 vermittelten krankheiten
NO20062021L (no)	2006-07-07	Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika